Tempus AI, Inc.
TEM
Κατάταξη σε μετοχές
#1885
Tempus AI, Inc. operates as a healthcare technology company in the United... Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Τιμή μετοχής
$64.29
Τελευταίος συγχρονισμός: 2026-10-16
Κεφαλαιοποίηση
$11.28B
Αλλαγή (1 ημέρα)
-9.62%
Αλλαγή (1 έτος)
-26.76%
Χώρα
US
Εμπόριο Tempus AI, Inc. (TEM)
Κατηγορία
Healthcare
EPS για Tempus AI, Inc. (TEM)
EPS στις June 2026 TTM: $-1.43
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Tempus AI, Inc., το τρέχον EPS της εταιρείας (TTM) είναι $-1.43. Στο τέλος του 2023, η εταιρεία είχε EPS $-1.73, μείωση σε σύγκριση με το EPS του 2022 που ήταν $-1.97.
Ιστορικό EPS της Tempus AI, Inc. από 2019 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-1.43 | -68.91% |
| 2024 | $-4.60 | 166.85% |
| 2023 | $-1.73 | -12.24% |
| 2022 | $-1.97 | 12.15% |
| 2021 | $-1.75 | 17.27% |
| 2020 | $-1.49 | 62.46% |
| 2019 | $-0.92 | 0.00% |
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $3.48 | -343.36% |
US
|
|
| $1.79 | -225.27% |
AU
|
|
| $1.43 | -200.00% |
US
|
|
| $-0.59 | -58.74% |
US
|
|
| - | - |
US
|
